Understanding Human Factors and Labeling Issues Unique to Combination Product Devices Combination products, which comprise both drug and device components, present unique challenges in terms of human factors and labeling. These issues can impact regulatory compliance and market success for manufacturers. This comprehensive guide aims to walk regulatory affairs (RA), quality assurance (QA), and clinical professionals through the complexities associated with human factors and labeling in combination products within the context of FDA regulations and guidance. Overview of Combination Products Combination products include any therapeutic product that combines a drug and a device or two or more regulated components (e.g.,…

Case Studies of Combination Product Submissions and Review Challenges In the evolving landscape of healthcare, combination products, defined as therapeutic and diagnostic products that combine drugs, devices, and/or biological products, have gained significant importance. Regulatory pathways for these combination products can be complex, requiring careful navigation through the FDA’s guidelines and requirements. This article serves as an instructional guide for regulatory, quality, clinical, and RA/QA professionals in understanding the submission and review challenges of combination products, specifically focusing on the regulatory pathways associated with drug-device and biologic-device combinations. Understanding Combination Products Combination products are categorized by the primary mode of…

Design Control and GMP Expectations for Integrated Combination Product Teams The landscape of regulatory compliance for combination products has become increasingly sophisticated as the market evolves and innovations emerge. This guide aims to provide a comprehensive overview of the design control and Good Manufacturing Practice (GMP) expectations specific to combination products, particularly for regulatory, quality, clinical, and RA/QA professionals engaged in the drug–device and biologic–device regulatory pathways. Understanding Combination Products Combination products are defined by the FDA as therapeutic and diagnostic products that combine drugs, devices, and/or biological products. They can take various forms, such as a drug-coated stent or…

How FDA assigns primary mode of action and lead center for combination products Understanding FDA’s Assignment of Primary Mode of Action and Lead Center for Combination Products Introduction to Combination Products Combination products are defined by the US Food and Drug Administration (FDA) as therapeutic and diagnostic products that combine drugs, devices, and/or biological products. According to FDA regulations, these products must meet the regulatory standards applicable to both their constituent parts, thereby requiring specialized knowledge and compliance strategies from regulatory professionals. The classification and regulation of combination products are critical, as they can significantly affect not only market entry…

Regulatory Pathways for Drug-Device and Biologic-Device Combination Products In the rapidly evolving landscape of healthcare, combination products that integrate both drugs and devices, as well as biologics and devices, have become increasingly significant. The U.S. Food and Drug Administration (FDA) has established regulatory pathways to ensure the safety and efficacy of these products. This tutorial aims to guide regulatory, quality, clinical, and RA/QA professionals through the complexities of these regulations, providing an in-depth understanding of the pathways and compliance requirements necessary for approval in the U.S., UK, and EU markets. Understanding Combination Products A combination product is defined as a…

Global Alignment of US FDA Combination Product Rules with EU Regulations In today’s rapidly evolving regulatory landscape, understanding the intersection of US FDA combination product regulations and EU frameworks is critical for professionals working in the field of medical devices, drugs, and biologics. This article offers a comprehensive guide to the combined regulatory pathways for combination products in the US, UK, and EU, emphasizing critical aspects such as primary mode of action, coordination between the Office of Pharmaceutical Quality (OPQ) and the Center for Devices and Radiological Health (CDRH), and the essential considerations for good manufacturing practices (GMP) and post-market…

Combination Product Quality Systems and the QSIT Inspection Model The increasing complexity of combination products, which integrate drugs, devices, and biological products, necessitates a robust understanding of the regulatory frameworks ensuring their safety and efficacy. As regulatory professionals in the pharmaceutical and medical device sectors, it is critical to comprehend how to adequately apply quality systems within combination products and how these systems are evaluated during inspections, particularly through the Quality System Inspection Technique (QSIT). This article provides a step-by-step tutorial on the quality systems applicable to combination products and the QSIT model used by the FDA. Understanding Combination Products…

Strategies for Platform Devices Used with Multiple Drugs or Biologics This comprehensive tutorial will provide regulatory professionals with a step-by-step guide on the strategies for managing combination products that incorporate platform devices used with multiple drugs or biologics. Specifically, the focus will be on the regulatory pathways designed for these products, ensuring compliance with FDA regulations, and navigating the complexities these products entail. This guide is particularly relevant for professionals working within the realms of regulatory affairs, quality assurance, clinical, and quality control in the context of medical devices. Understanding Combination Products The FDA classifies products that combine drugs, devices,…

Post Market Safety Reporting Rules for Combination Products and Their Components Understanding the complexities of post-market safety reporting for combination products is essential for regulatory, quality, clinical, and RA/QA professionals involved in medical devices and combination products. The U.S. Food and Drug Administration (FDA) mandates specific reporting guidelines that ensure public safety and product efficacy. This guide aims to provide a comprehensive overview of the rules, focusing on the regulatory pathways, coordination between offices, and the significance of post-market safety reporting. 1. Overview of Combination Products Combination products are defined by the FDA as products that are composed of two…

Bridging Drug and Device Stability, Shelf Life and Packaging Information Introduction to Combination Products Combination products are defined by the U.S. Food and Drug Administration (FDA) as products that combine a drug, a device, or biological product. Understanding the interplay between these components is essential, particularly regarding stability, shelf life, and packaging information. The FDA classifies these products based on their primary mode of action (PMOA), which can significantly influence regulatory pathways and requirements. In this comprehensive guide, we will delve into the nuances of ensuring compliance in these critical areas of combination products. Our exploration will include the regulatory…